346 EFFICACY AND SAFETY OF TEVERELIX LA, A NEW GNRH ANTAGONIST IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA (BPH). RESULTS FROM A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE, MULTINATIONAL STUDY INVESTIGATING TWO SINGLE INJECTIONS OF 60 MG AT 48 HOURS INTERVAL ADMINISTERED S.C. TO TREATMENT NAÏVE PATIENTS SUFFERING FROM BPH